Manufacturers interfering with access to 340B drugs prohibition extension

This bill extends a prohibition preventing drug manufacturers from interfering with access to 340B drugs for healthcare providers. It directly affects hospitals and clinics participating in the federal 340B drug pricing program, which allows them to purchase medications at discounted rates. The key mechanism is repealing the existing expiration date (July 1, 2027) in Minnesota law, ensuring the prohibition remains in effect beyond that date without requiring new legislation. The bill maintains current policy without creating new requirements or altering the 340B program's structure.